Search clinical trials for: GSK189075A

Total 17 results

GlaxoSmithKline

Completed

A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
GlaxoSmithKline

Completed

Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive

Diabetes Mellitus, Type 2

United States, Canada, Germany, Estonia, Russian Federation, South Africa, India, Ukraine, Mexico, Greece, New Zealand, Poland, Czechia, Lithuania, Romania, Puerto Rico
GlaxoSmithKline

Completed

Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

Obesity | Diabetes Mellitus, Type 2

United Kingdom
GlaxoSmithKline

Completed

A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

United States
GlaxoSmithKline

Completed

A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

Diabetes Mellitus, Type 2 | Renal Insufficiency | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Non-Insulin-Dependent Diabetes Mellitus

Germany, United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)

Diabetes Mellitus, Type 2

United States, Argentina, Poland, Germany, Bulgaria, Peru, Russian Federation, Mexico, Hungary, South Africa, Latvia, New Zealand, Costa Rica, India, Czechia, Romania, Lithuania, Puerto Rico, Chile
GlaxoSmithKline

Completed

A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >/ 2000mg of Metformin

Diabetes Mellitus, Type 2

Argentina, Germany, United States
GlaxoSmithKline

Completed

Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

Mexico
GlaxoSmithKline

Completed

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

Diabetes Mellitus, Type 2

United States

Search clinical trials for: GSK189075A

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations